Day: July 28, 2022

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages 17 Education & Technology Group Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm – YQ

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of 17 Education & Technology Group Inc. (NASDAQ: YQ) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with 17EdTech’s December 2020 initial public offering […]

Read More . .

Innodisk Announces Launch of Edge AI SSDs

TAIPEI, July 28, 2022 /PRNewswire/ — Innodisk, a global leader in industrial-grade storage and embedded peripherals, is pushing the development of edge AI technology, and in doing so has officially launched a new edge computing solid-state drive (SSD) product line, consisting of the 2.5″ SATA 3TS6-P, 3TS9-P and M.2 (P80) 4TS2-P drives. Innodisk’s new edge AI SSDs […]

Read More . .

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Discover Financial Services Investors to Inquire About Securities Class Action Investigation – DFS

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigative potential securities claims on behalf of shareholders of Discover Financial Services (NYSE: DFS) resulting from allegations that Discover Financial Services may have issued materially misleading business information to the investing public. SO WHAT: If […]

Read More . .

Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women – Findings from HPTN 084 Study

DURHAM, N.C., July 28, 2022 (GLOBE NEWSWIRE) — Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (CAB) for pre-exposure prophylaxis (PrEP) study at the AIDS 2022 conference in Montreal. New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November […]

Read More . .